Natacha Bessis

Natacha Bessis

Auto-generated profile, based on publicly available information

Natacha Bessis

Inserm UMR‐1125 and Université Sorbonne Paris Nord Bobigny France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JBJérôme Biton
Jérôme Biton
LSLuca Semerano
Luca Semerano
LDLaure Delavallée
Laure Delavallée
DLDelphine Lemeiter
Delphine Lemeiter
MLMarion Laborie
Marion Laborie
NBNatacha Bessis
Natacha Bessis
CD4+CD25+Foxp3+ regulatory T cells (Treg) are involved in several autoimmune diseases, including rheumatoid arthritis. TNF-α blockers induce therapeutic benefits in rheumatoid arthritis via a variety of mechanisms. We aimed to characterize the impact on Treg of TNF-α overexpression in vivo and of TNF-α inhibiting treatments. We used human TNF-α transgenic mice as a model of strictly TNF-α–dependent arthritis. Our study showed that initial Treg frequency was lower in TNF-α transgenic mice than in wild-type mice. However, the course of arthritis was marked by elevation of Treg frequency and a dramatic increase in expression of TNFR2. Antagonizing TNF-α with either the anti-human TNF-α Ab (infliximab) or active immunotherapy (TNF-kinoid) increased the Treg frequency and upregulated CTLA-4, leading to enhancement of suppressor activity. Moreover, both anti–TNF-α strategies promoted the differentiation of a CD62L− Treg population. In conclusion, in an in vivo model of TNF-α–driven arthritis, Treg frequency increased with inflammation but failed to control the inflammatory process. Both passive and active TNF-α–inhibiting strategies restored the suppressor activity of Treg and induced the differentiation of a CD62L− Treg population.

1 September 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JBJérôme Biton
Jérôme Biton
SASara Khaleghparast Athari
Sara Khaleghparast Athari
ATAllan Thiolat
Allan Thiolat
FSFrançois Santinon
François Santinon
DLDelphine Lemeiter
Delphine Lemeiter
NBNatacha Bessis
Natacha Bessis
IL-33 is strongly involved in several inflammatory and autoimmune disorders with both pro- and anti-inflammatory properties. However, its contribution to chronic autoimmune inflammation, such as rheumatoid arthritis, is ill defined and probably requires tight regulation. In this study, we aimed at deciphering the complex role of IL-33 in a model of rheumatoid arthritis, namely, collagen-induced arthritis (CIA). We report that repeated injections of IL-33 during induction (early) and during development (late) of CIA strongly suppressed clinical and histological signs of arthritis. In contrast, a late IL-33 injection had no effect. The cellular mechanism involved in protection was related to an enhanced type 2 immune response, including the expansion of eosinophils, Th2 cells, and type 2 innate lymphoid cells, associated with an increase in type 2 cytokine levels in the serum of IL-33–treated mice. Moreover, our work strongly highlights the interplay between IL-33 and regulatory T cells (Tregs), demonstrated by the dramatic in vivo increase in Treg frequencies after IL-33 treatment of CIA. More importantly, Tregs from IL-33–treated mice displayed enhanced capacities to suppress IFN-γ production by effector T cells, suggesting that IL-33 not only favors Treg proliferation but also enhances their immunosuppressive properties. In concordance with these observations, we found that IL-33 induced the emergence of a CD39high Treg population in a ST2L-dependent manner. Our findings reveal a powerful anti-inflammatory mechanism by which IL-33 administration inhibits arthritis development.

1 September 2014 in Cytokine
Verified
Journal Article
Closed access
ATA. Thiolat
A. Thiolat
ADA. Denys
A. Denys
MPM. Petit
M. Petit
JBJ. Biton
J. Biton
DLD. Lemeiter
D. Lemeiter
NBN. Bessis
N. Bessis

1 February 2003 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
NSNathalie Saidenberg-Kermanac'H
Nathalie Saidenberg-Kermanac'H
NBNatacha Bessis
Natacha Bessis
VDVirginie Deleuze
Virginie Deleuze
CBCarole Bloquel
Carole Bloquel
MBMichel Bureau
Michel Bureau
MBMarie-Christophe Boissier
Marie-Christophe Boissier

14 October 2019 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
FSFrançois Santinon
François Santinon
MBMaxime Batignes
Maxime Batignes
MMMajda Lyna Mebrek
Majda Lyna Mebrek
JBJerôme Biton
Jerôme Biton
GCGaëlle Clavel
Gaëlle Clavel
NBNatacha Bessis
Natacha Bessis

16 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
GHGuillaume Harlé
Guillaume Harlé
CKCamille Kowalski
Camille Kowalski
JDJuan Dubrot
Juan Dubrot
DBDale Brighouse
Dale Brighouse
GCGaëlle Clavel
Gaëlle Clavel
SHStéphanie Hugues
Stéphanie Hugues
Lymphatic endothelial cells (LECs) present peripheral tissue antigens to induce T cell tolerance. In addition, LECs are the main source of sphingosine-1-phosphate (S1P), promoting naive T cell survival and effector T cell exit from lymph nodes (LNs). Autophagy is a physiological process essential for cellular homeostasis. We investigated whether autophagy in LECs modulates T cell activation in experimental arthritis. Whereas genetic abrogation of autophagy in LECs does not alter immune homeostasis, it induces alterations of the regulatory T cell (T reg cell) population in LNs from arthritic mice, which might be linked to MHCII-mediated antigen presentation by LECs. Furthermore, inflammation-induced autophagy in LECs promotes the degradation of Sphingosine kinase 1 (SphK1), resulting in decreased S1P production. Consequently, in arthritic mice lacking autophagy in LECs, pathogenic Th17 cell migration toward LEC-derived S1P gradients and egress from LNs are enhanced, as well as infiltration of inflamed joints, resulting in exacerbated arthritis. Our results highlight the autophagy pathway as an important regulator of LEC immunomodulatory functions in inflammatory conditions.